News

Manipal Health Enterprises Ltd share price declined by 2.73% to Rs 724.25. The Company`s net profit surged by 30.50% to Rs 243.43 crore, while revenue from operations improved marginally 7.23% to Rs 3090.63 crore in Q2FY26 over Q1FY26. The market capitalization of Hospital industry group stocks on BSE stood at Rs 5.23 lakh crore, easing 7.46%. It has eased by 1.61% over last one week and spiked sharply by 25.80% in last one month while the market capitalization of Manipal Health Enterprises Ltd has remained flat Profit before tax (PBT) of Manipal Health Enterprises Ltd stood at Rs 315.18 crore in Q2 FY26, slipping 8.43% year-on-year, and surging by 29.23% quarter-on-quarter. EBITDA came in at Rs 662 crore, rallying 23.03% YoY and gaining 0.97% sequentially. Total expenses saw a slight increase of 6.96% to Rs 2541.27 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 462.01 crore, jumping 18.03% YoY. For the TTM ended FY26, revenue from operations surged 25.40% to Rs 10335.75 crore, while net profit contracted by 15.26% to Rs 916.59 crore, compared to previous TTM. EBITDA soared by 217771% to Rs 2426.47 crore, and PBT slipped by 5.17% to Rs 1178.1 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 2078.4 crore in FY26, as against Rs 1569.83 crore in FY25.

Manipal Health Enterprises Limited has signed a Business Transfer Agreement with Kindorama Healthcare Private Limited to acquire the entire operations of the Kinder Women’s Hospital and Fertility Centre in Bengaluru, Karnataka, for a cash consideration of Rs 130 crore. The acquisition, which is allied to Manipal Hospitals` current business and expected to be completed within 90 days, will add a facility with 100 beds and revenue of Rs 20.75 crore for the fiscal year ended March 31, 2026.

Manipal Health Enterprises Limited will hold a board meeting on Thursday, August 20, 2026, to consider and approve the unaudited financial results for both standalone and consolidated entities for the quarter ended June 30, 2026, along with a limited review report from statutory auditors; the company previously closed the trading window for its equity shares from August 5, 2026, until 48 hours after the financial results are made public.